NO20043611L - Fremgangsmate for fremstilling av HMG-COA reduktaseinhibitorer - Google Patents
Fremgangsmate for fremstilling av HMG-COA reduktaseinhibitorerInfo
- Publication number
- NO20043611L NO20043611L NO20043611A NO20043611A NO20043611L NO 20043611 L NO20043611 L NO 20043611L NO 20043611 A NO20043611 A NO 20043611A NO 20043611 A NO20043611 A NO 20043611A NO 20043611 L NO20043611 L NO 20043611L
- Authority
- NO
- Norway
- Prior art keywords
- hmg
- preparation
- coa reductase
- reductase inhibitors
- sub
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av en forbindelse med formel. eller et salt, særlig et farmasøytisk akseptabelt salt med en base, derav eller et lakton derav hvori element representerer -CH-CH- eller -CH=CH- og R representerer en cyklisk rest.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35378702P | 2002-01-31 | 2002-01-31 | |
PCT/EP2003/000954 WO2003064392A1 (en) | 2002-01-31 | 2003-01-30 | Process for the manufacture of hmg-coa reductase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20043611L true NO20043611L (no) | 2004-08-30 |
NO327091B1 NO327091B1 (no) | 2009-04-20 |
Family
ID=27663254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20043611A NO327091B1 (no) | 2002-01-31 | 2004-08-30 | Fremgangsmate for fremstilling av en enantiomerisk ren form eller en racemisk form av HMG-COA reduktaseinhibitorer |
Country Status (23)
Country | Link |
---|---|
US (2) | US7371865B2 (no) |
EP (1) | EP1472228B1 (no) |
JP (1) | JP4524111B2 (no) |
KR (1) | KR20040081161A (no) |
CN (1) | CN1305853C (no) |
AT (1) | ATE426594T1 (no) |
AU (1) | AU2003226971B2 (no) |
BR (1) | BR0307303A (no) |
CA (1) | CA2472776C (no) |
CO (1) | CO5601005A2 (no) |
DE (1) | DE60326819D1 (no) |
EC (1) | ECSP045214A (no) |
ES (1) | ES2323267T3 (no) |
HK (1) | HK1070651A1 (no) |
IL (1) | IL162980A (no) |
MX (1) | MXPA04007396A (no) |
NO (1) | NO327091B1 (no) |
NZ (1) | NZ534232A (no) |
PL (1) | PL370658A1 (no) |
PT (1) | PT1472228E (no) |
RU (1) | RU2299196C2 (no) |
WO (1) | WO2003064392A1 (no) |
ZA (1) | ZA200405322B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2513837A1 (en) * | 2003-02-12 | 2004-08-26 | Paul Adriaan Van Der Schaaf | Crystalline forms of pitavastatin calcium |
KR20060006052A (ko) * | 2003-04-24 | 2006-01-18 | 다이셀 가가꾸 고교 가부시끼가이샤 | 에틸(3r,5s,6e)-7-[2-시클로프로필-4-(4-플루오로페닐)퀴놀린-3-일]-3,5-디히드록시-6-헵테노에이트의 제조 방법 |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
EP1817027A2 (en) * | 2004-09-27 | 2007-08-15 | Ranbaxy Laboratories Limited | Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
SI2024341T1 (sl) * | 2006-05-03 | 2016-04-29 | Msn Laboratories Private Limited | Novi postopek za statine in njihove farmacevtsko sprejemljive soli |
EP2086945B1 (en) * | 2006-10-09 | 2016-01-06 | MSN Laboratories Private Limited | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof |
US20090076292A1 (en) | 2007-04-18 | 2009-03-19 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and process for the preparation of rosuvastatin |
JP2010533188A (ja) * | 2007-07-12 | 2010-10-21 | テバ ファーマシューティカル インダストリーズ リミティド | ロバスタチン中間体及びその製法 |
WO2010089770A2 (en) * | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof |
KR101160152B1 (ko) * | 2009-02-24 | 2012-06-27 | 한미사이언스 주식회사 | 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물 |
WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
JP2013519666A (ja) * | 2010-02-23 | 2013-05-30 | カディラ・ヘルスケア・リミテッド | Hmg−coaレダクターゼ阻害剤およびその調製のための方法 |
EP2383260A3 (en) | 2010-04-30 | 2011-12-28 | Dipharma Francis S.r.l. | Process for the preparation of statins |
WO2011141934A1 (en) | 2010-05-13 | 2011-11-17 | Matrix Laboratories Ltd. | An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors |
CN103025727B (zh) * | 2010-07-01 | 2015-09-02 | 柳韩洋行 | HMG-CoA还原酶抑制剂及其中间体的制备方法 |
EP2638013A4 (en) * | 2010-11-12 | 2014-03-26 | Hetero Research Foundation | NEW POLYMORPHS OF CALCIUM PIVASTATIN |
JP6181063B2 (ja) | 2011-11-28 | 2017-08-16 | マイラン ラボラトリーズ リミテッドMylan Laboratories Limited | HMG−CoAレダクターゼ阻害剤の中間体の新規な製造方法 |
CN103288871A (zh) * | 2012-02-28 | 2013-09-11 | 浙江京新药业股份有限公司 | 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用 |
ITVI20130039A1 (it) | 2013-02-20 | 2014-08-21 | F I S Fabbrica Italiana Sint I S P A | Processo per la preparazione di intermedi chiave per la sintesi di statine |
CN103172656B (zh) * | 2013-04-02 | 2015-07-08 | 浙江科技学院 | 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺 |
CN111518035A (zh) * | 2020-06-18 | 2020-08-11 | 安徽鼎旺医药有限公司 | 一种瑞舒伐他汀叔丁胺盐及其制备方法 |
CN113683539B (zh) * | 2021-09-23 | 2023-05-16 | 上海裕兰生物科技有限公司 | 一种聚酮中间体的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4650890A (en) * | 1984-04-03 | 1987-03-17 | Sandoz Corp. | Preparation of olefinic compounds and intermediates thereof |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
US5049577A (en) * | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
JP3528186B2 (ja) | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
EP1341785B1 (en) * | 2000-11-16 | 2008-10-08 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
EP1365029A4 (en) * | 2001-02-02 | 2009-07-29 | Mitsubishi Chem Corp | PROCESS FOR PRODUCING ACID ESTERS (3R, 5S) - (E) -7- 2-CYCLOPROPYL-4- (4-FLUOROPHENYL) -QUINOLIN-3-YL-3,5-DIHYDROXYHEPT-6-ENIC |
TWI243165B (en) * | 2001-11-14 | 2005-11-11 | Nissan Chemical Ind Ltd | Process for producing optically active oxoheptenoic acid ester |
US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
GB0210234D0 (en) * | 2002-05-03 | 2002-06-12 | Novartis Ag | Process for the manufacture of organic compounds |
-
2003
- 2003-01-30 CN CNB038027402A patent/CN1305853C/zh not_active Expired - Lifetime
- 2003-01-30 EP EP03734716A patent/EP1472228B1/en not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011808A patent/KR20040081161A/ko active IP Right Grant
- 2003-01-30 NZ NZ534232A patent/NZ534232A/xx not_active IP Right Cessation
- 2003-01-30 RU RU2004126442/04A patent/RU2299196C2/ru not_active IP Right Cessation
- 2003-01-30 US US10/502,177 patent/US7371865B2/en not_active Expired - Lifetime
- 2003-01-30 WO PCT/EP2003/000954 patent/WO2003064392A1/en active Application Filing
- 2003-01-30 PL PL03370658A patent/PL370658A1/xx not_active Application Discontinuation
- 2003-01-30 BR BR0307303-3A patent/BR0307303A/pt not_active IP Right Cessation
- 2003-01-30 ES ES03734716T patent/ES2323267T3/es not_active Expired - Lifetime
- 2003-01-30 DE DE60326819T patent/DE60326819D1/de not_active Expired - Lifetime
- 2003-01-30 PT PT03734716T patent/PT1472228E/pt unknown
- 2003-01-30 AU AU2003226971A patent/AU2003226971B2/en not_active Ceased
- 2003-01-30 JP JP2003564015A patent/JP4524111B2/ja not_active Expired - Lifetime
- 2003-01-30 MX MXPA04007396A patent/MXPA04007396A/es active IP Right Grant
- 2003-01-30 CA CA2472776A patent/CA2472776C/en not_active Expired - Fee Related
- 2003-01-30 AT AT03734716T patent/ATE426594T1/de active
-
2004
- 2004-07-05 ZA ZA2004/05322A patent/ZA200405322B/en unknown
- 2004-07-12 IL IL162980A patent/IL162980A/en not_active IP Right Cessation
- 2004-07-30 EC EC2004005214A patent/ECSP045214A/es unknown
- 2004-08-10 CO CO04077715A patent/CO5601005A2/es not_active Application Discontinuation
- 2004-08-30 NO NO20043611A patent/NO327091B1/no not_active IP Right Cessation
-
2005
- 2005-04-18 HK HK05103286.2A patent/HK1070651A1/xx not_active IP Right Cessation
-
2008
- 2008-03-24 US US12/054,193 patent/US20080182873A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003064392A1 (en) | 2003-08-07 |
NZ534232A (en) | 2006-03-31 |
CN1305853C (zh) | 2007-03-21 |
EP1472228B1 (en) | 2009-03-25 |
DE60326819D1 (de) | 2009-05-07 |
ZA200405322B (en) | 2005-07-27 |
RU2004126442A (ru) | 2005-06-10 |
CO5601005A2 (es) | 2006-01-31 |
AU2003226971B2 (en) | 2006-11-30 |
BR0307303A (pt) | 2005-01-11 |
JP4524111B2 (ja) | 2010-08-11 |
US20080182873A1 (en) | 2008-07-31 |
CA2472776A1 (en) | 2003-08-07 |
ATE426594T1 (de) | 2009-04-15 |
MXPA04007396A (es) | 2004-10-11 |
CA2472776C (en) | 2011-01-25 |
KR20040081161A (ko) | 2004-09-20 |
EP1472228A1 (en) | 2004-11-03 |
US20050070605A1 (en) | 2005-03-31 |
ES2323267T3 (es) | 2009-07-10 |
PT1472228E (pt) | 2009-06-24 |
ECSP045214A (es) | 2004-09-28 |
HK1070651A1 (en) | 2005-06-24 |
PL370658A1 (en) | 2005-05-30 |
CN1622937A (zh) | 2005-06-01 |
JP2005520814A (ja) | 2005-07-14 |
US7371865B2 (en) | 2008-05-13 |
RU2299196C2 (ru) | 2007-05-20 |
IL162980A (en) | 2010-02-17 |
NO327091B1 (no) | 2009-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1070651A1 (en) | Process for the manufacture of hmg-coa reductase inhibitors | |
EP2292209A3 (en) | Stable pharmaceutical composition comprising a pyramidine-sulfamide | |
MA27624A1 (fr) | Procede pour realiser une preparation enrobee | |
RS51444B (sr) | JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa | |
CA2506016A1 (en) | 3-amino-piperidine derivatives and processes for their preparation | |
WO2004082822A3 (en) | Methods for isolating crystalline form i of 5-azacytidine | |
EP1775289A4 (en) | NEW IMIDAZOLIDINE DERIVATIVES | |
EP2308828A3 (en) | CaSR antagonist | |
EA200400491A1 (ru) | Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции | |
EA200500862A1 (ru) | Синоменин и соединения синоменина, синтез и применение | |
NO20062656L (no) | Fremgangsmate for fremstilling av statiner | |
EP1975164A3 (en) | Octahydrobenzimidazolone compounds as analgetics | |
EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
EP2388002A3 (en) | Antidepressant containing heterocyclic compound having specific structure | |
MXPA05013584A (es) | Compuesto amina terciaria ciclica. | |
EA200301120A1 (ru) | Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена | |
MXPA04000357A (es) | COMPUESTO QUE CONTIENE AMIDA Y TIENE UNA MEJOR SOLUBILIDAD, Y MeTODO PARA MEJORAR LA SOLUBILIDAD DE UN COMPUESTO QUE CONTIENE AMIDA. | |
MY138826A (en) | 2,7-substituted indoles | |
ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
DE60330758D1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
ATE516031T1 (de) | Verbindungen gegen krebs | |
EP2266971A3 (en) | Hiv protease inhibiting compounds | |
DK1209151T3 (da) | 4-substituerede piperidinderivativer | |
GB0212410D0 (en) | Organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |